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The glycosaminoglycan hyaluronan (HA), a major component of extracellular matrices,
and cell surface receptors of HA have been proposed to have pivotal roles in cell
proliferation, migration, and invasion, which are necessary for inflammation and can-
cer progression. CD44 and receptor for HA-mediated motility (RHAMM) are the two
main HA-receptors whose biological functions in human and murine inflammations and
tumor cells have been investigated comprehensively. HA was initially considered to
be only an inert component of connective tissues, but is now known as a “dynamic”
molecule with a constant turnover in many tissues through rapid metabolism that
involves HA molecules of various sizes: high molecular weight HA (HMW HA), low
molecular weight HA, and oligosaccharides. The intracellular signaling pathways initiated
by HA interactions with CD44 and RHAMM that lead to inflammatory and tumori-
genic responses are complex. Interestingly, these molecules have dual functions in
inflammations and tumorigenesis. For example, the presence of CD44 is involved in
initiation of arthritis, while the absence of CD44 by genetic deletion in an arthritis
mouse model increases rather than decreases disease severity. Similar dual func-
tions of CD44 exist in initiation and progression of cancer. RHAMM overexpression is
most commonly linked to cancer progression, whereas loss of RHAMM is associated
with malignant peripheral nerve sheath tumor growth. HA may similarly perform dual
functions. An abundance of HMW HA can promote malignant cell proliferation and
development of cancer, whereas antagonists to HA-CD44 signaling inhibit tumor cell
growth in vitro and in vivo by interfering with HMW HA-CD44 interaction. This review
describes the roles of HA interactions with CD44 and RHAMM in inflammatory responses
and tumor development/progression, and how therapeutic strategies that block these
key inflammatory/tumorigenic processes may be developed in rodent and human
diseases.
Keywords: hyaluronan, CD44, RHAMM, inflammation, cancer
Abbreviations:CD44v, variant isoformof CD44; GAG, glycosaminoglycan;HA, hyaluronic; HAS, hyaluronan synthase; HMW
HA, high molecular weight HA; HYAL, hyaluronidase; LMW HA, low molecular weight HA; oHAs, HA oligosachharides;
PEG, polyethylene glycol; PEI, polyethyleneimine; PTX, paclitaxel; RHAMM, receptor of HA-mediatedmotility; RTK, receptor
tyrosine kinase; shRNA, short hairpin RNA; siRNA, short interfering RNA; Tf, transferrin.
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Introduction
The interplay between cells and with components in the extracel-
lular matrix (ECM) of the microenvironment is tightly regulated
during normal physiological processes of tissues and organs (1–
3). During inflammation and tumorigenesis, cellular communica-
tions are dramatically lost with subsequent extensive remodeling
of cellular and molecular composition of the tumor microenvi-
ronment, which supports inflammation, cancer cell proliferation
and migration/motility, invasion, and metastasis. Carcinogene-
sis is characterized by an inflammatory response where biolog-
ically active ECM fragments regulate tissue injury/remodeling.
Notably, the biosynthesis and degradation of the glycosamino-
glycan (GAG) hyaluronan (HA), a major component in ECMs,
is associated with the rapid matrix remodeling that occurs dur-
ing embryonic morphogenesis, inflammation, and tumorigenesis
(4–7).
Hyaluronan is a non-sulfated, linear GAG composed of repeat-
ing disaccharides of (β, 1–4)-glucuronic acid (GlcUA) and (β,
1-3)-N-acetyl glucosamine (GlcNAc) (MW~400Da) (Figure 1).
Native HA in most tissues has a high molecular mass of 1–10
million Da with extended molecular lengths of 2–20 µm (8–11).
HA has crucial roles in structuring tissue architecture, in cell
motility, in cell adhesion, and in proliferation processes (12, 13).
These cellular events are mediated mainly through two major
signal-transducing cell surface HA-receptors, CD44 (14–19) and
the receptor for HA-mediated motility (RHAMM) designated as
CD168 (20) (Figure 2), which was first described by Turley (21,
22) as a soluble HA-binding protein released by sub-confluent
migrating cells (23). HA is the principal ligand of CD44 (16), and
alternative splicing and differential glycosylation produce multi-
ple structural and functional versions of CD44 that are responsible
for proinflammatory activities, including cell–cell and cell–matrix
interactions (6, 24–26). TheCD44 ectodomain includes an amino-
terminal domain that contains a HA-binding “link module” motif
related to those in the HA-binding proteoglycans and the link
proteins (27). Like CD44, RHAMM is alternatively spliced, and
variant forms of RHAMM are found both on cell surfaces and
inside the cells (28, 29).However, they do not have the linkmodule
domain. They have a BX7B motif that also can bind to HA, where
“B” represents arginine or lysine, and “X” represents any non-
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FIGURE 1 | Native polymeric HA and degraded HA fragments. High
molecular weight (HMW500 disaccharide units; [β-1, 4-GlcUA-β-1,
3-GlcNAc]n synthesized in the normal homeostatic condition is degraded by
free radicals and hyaluronidases (HYAL1-2) during inflammation/tumorigenesis
when tissue injury occurs. These fragments are 50 disaccharide units. As a
result, the fragments of different molecular weights have different biological
functions. For example, intermediate fragments (30–500 kDa) can stimulate cell
proliferation while smaller fragments <50 kDa promote cell migration. HA
oligosaccharides down to three disaccharides can still bind to
CD44.
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FIGURE 2 | (A) Mouse CD44 and RHAMM gene/protein structures in mice.
Model structure of alternative splicing in CD44. CD44 pre-mRNA is encoded by
20 exons in mouse and 19 exons in human being. The common standard
CD44s (hematopoietic) form contains no extra exons, and the protein has a
serine motif encoded in exon 5 that can initiate synthesis of a chondroitin sulfate
or dermatan sulfate chain. Alternative splicing of CD44 predominantly involves
variable insertion of 10 extra exons with combinations of exons 6–15 and
spliced in v1–v10 into the stem region, of which v3 encodes a substitution site
for a heparan sulfate chain. Variable numbers of the v exons can be spliced in
epithelial cells, endothelial cells, and inflammatory monocytes and also are
upregulated commonly on neoplastic transformation depending on the tissue.
(B) Model structure of alternatively spliced CD44 proteins. The CD44 protein is
composed of an extracellular N-terminal domain, a stem region in the
extracellular domain close to the transmembrane region, where the variant exon
products (red/violet circles) are inserted, the transmembrane region, and the
carboxyl terminal cytoplasmic tail. There are multiple sites for N-glycosylation
(purple circles) and O-glycosylation (orange circles), and a sulfation domain. The
N-terminal portion contains highly conserved disulfide bonds as well as 2 BX7B
motifs, both of which are essential for HA binding. CD44 is subjected to
extensive glycosylation, sulfation, and attachment of GAGs that contribute to
regulation of the HA-binding activity. The C-terminal cytoplasmic tail contains
several phosphorylation sites that regulate the interaction of CD44 with the
cytoskeletal linker proteins, as well as with SRC kinases. (C) RHAMM exon
structure. The full-length protein (85 kDa in human beings) is largely associated
with microtubule formation during the cell cycle progression. Three isoforms are
generated by alternative splicing of exon 4, 5, or 13. Loss of exon 4 disrupts
association with microtubules and results in the appearance of RHAMM in the
cell nucleus. N-terminal truncations that may be generated by a
posttranslational mechanism are constitutively present in some aggressive
breast cancer cell lines and tumors. These accumulate in the nucleus and on
the cell surface. (D) The secondary structure of RHAMM. RHAMM can
self-associate to form random coiled coils (132).
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migration during inflammation, wound healing, and tumorige-
nesis can require surface expression of RHAMM. However, the
mechanism of cooperativity between RHAMM and CD44 is not
clearly understood. In this review, we discuss the nature of such
interactions and the important therapeutics that can target CD44
and RHAMM in inflammation and cancer.
HA in Inflammation and Cancer
Biology of HA
Hyaluronan is a ubiquitous component of tissue ECM found in
a native homeostatic form within hydrated tissues such as the
vitreous of the eye, articular cartilage, synovial fluid, lymphatics,
and skin. HA is present in interstitial collagenous matrices and
increases viscosity and hydration. This impedes fluid flow through
matrices by forming a barrier (31). HA is found in pericellular
matrices attached to the HA-synthesizing enzymes or its receptors
and is also present in intracellular degradation compartments (6,
7, 32–37). HA differs from the other GAGs: it is not synthesized
on a core protein as a proteoglycan in the Golgi. Instead it is syn-
thesized by single transmembraneHA synthases (HAS1, HAS2, or
HAS3) at the inner face of the plasma membrane. The cytoplas-
mic active HAS sites alternately add the UDP-GlcUA and UDP-
GlcNAc substrates to the reducing, UDP-anchored elongating HA
molecule that is being systematically extruded through the plasma
membrane into the ECM to form the very long, unmodified
HA macromolecules without any sulfated or epimerized uronic
acid residues (23, 38). The HAS isozymes (HAS1, HAS2, HAS3)
differ from each other in their catalytic activities as well as in
the sizes of the synthesized HA. HAS1 and HAS2 polymerize
long high molecular weight (HMW) chains while HAS3 pro-
duces predominantly shorter lowmolecular weight (LMW) chains
(<300 kDa), and HAS3 appears to be more active than HAS1 and
HAS2 (38–40).
While its structure is simple, HA is an extraordinarily versatile
macromolecule. Its biophysical properties provide HA with func-
tions that influence the hydration and biomechanical properties of
different tissues, especially those of the vitreous humor in the eye,
the synovial joint fluid, and the dermis (41). In addition, HA also
interacts with extracellular macromolecules and HA-binding pro-
teoglycans, including versican and aggrecan, which are important
in the assembly of ECMs and of pericellular glycocalyces that can
act as protective cellular barriers and are essential for the assembly
and structure of many tissues (41–44). For example, increased
levels of aggrecan immobilized onHA in collagen networks resists
the variable compressive loads essential for the physical properties
of cartilages (45).
Successful morphogenesis also relies on physical properties of
HA as well as on signaling events triggered by HA-CD44 and/or
HA-RHAMM interactions. During embryogenesis, HA promotes
proliferation and migration of undifferentiated stem cells to sites
of organ development (26). Importantly, Has2 null mice fail
to synthesize HA during cardiac cushion development, and the
endothelial cushion cells do not undergo mesenchymal transfor-
mation (EMT) and cannot form the underlying connective tissue,
which leads to midgestational death (5, 46). Recent studies also
indicate that the matricellular protein periostin binding to the
integrins activates the HA synthesis and HA-mediated Akt/PKB
and focal adhesion kinase (FAK)/Erk signaling pathways, which
by feedback loop, further sustains Has2 expression for cell sur-
vival, and importantly, differentiation of embryonic cardiacmitral
valve cells (47) (Figure 3B).
Hyaluronan turnover is important for the maintenance of tis-
sue homeostasis, and ~30% of HA is replaced by newly formed
HA per 24 h (48). Removal of HA occurs by endocytic uptake
within the tissue, especially in lymph nodes and liver. Impor-
tantly, the presence of reactive oxygen species (ROS) enhances
HA turnover (49–51). Internalization and degradation of HA
is triggered by its binding to CD44 (52) and/or lymphatic ves-
sel endothelial receptor-1 (LYVE-1), which is expressed in lym-
phatic endothelium (53). HA is degraded into monosaccharides
by three enzymatic reactions. Hyaluronidases (HYALs) degrade
HA to oligosaccharides, which are then digested into GlcUA and
GlcNAc by β--glucuronidase and β-N-acetyl--hexosaminidase
(54, 55). In human beings, there are six HYAL genes, HYAL1-
4, HYAL-P1, and sperm-specific PH-20 (54, 56–58). These
enzymes can have different catalytic profiles. For example; HYAL1
degrades HA into oligosaccharides while HYAL2 degrades HMW
HA into fragments of intermediate size (~20 kDa). PH-20 is
anchored to the sperm acrosomal membrane through a glycosyl-
phosphatidylinositol (GPI) moiety, which promotes penetration
of spermatozoa through the HA matrix in cumulus-oocyte com-
plexes for fertilization (54, 59). In recent years, recombinant
human PH20 devoid of the GPI anchor has been prepared (60)
and tested for increasing drug penetration in skin and pancreatic
tumors in an animal model (61).
As mentioned earlier, under physiological conditions, HA
exists as a HMW polymer >106 Da providing structural frame-
works for cells. Such HMW HA functions as an extracellular
molecule transmitting signals and regulates a variety of cell behav-
iors, including cell adhesion, motility, and growth (6, 8–11, 37).
HA chains up to 20MDa are involved in ovulation, embryoge-
nesis, wound repair, and tissue regeneration (62). In malignant
cells, HA polysaccharides (>106Da) are abundant. HA levels can
be increased around tumor cells themselves or within the tumor
stroma to maintain normal cellular functions of the tumor cells.
Because of the close association of highHA levels withmalignancy
in many tumor types (37) considerable experimental evidence
implicates HA and its main receptor CD44 variants in tumor
progression both in cell and animal models (6, 25, 37, 63–69).
HMWHA induce activation of tyrosine kinase in endothelial cells
and Ras-transformed fibroblasts at lower level (70, 71) compared
to fragmented HA (71). However, the ability of the naked mole
rat to synthesize high molecular mass HA (five times larger than
human HA) is correlated to the cancer resistance and longevity
of naked mole rat (72), but this animal is a rare species. A
recent study established that reducing HAS levels using antisense
techniques suppresses tumor growth, but showed that extremely
high HA levels also inhibit tumor growth, possibly by suppressing
cell–cell interactions, or ligand access to cell surface receptors
(73). Remarkably, following tissue injury, HA and its degraded
fragments<5 105 Da size accumulate. Such smaller size HAwas
shown to be crucial for the production of cytokine and chemokine
for differentiation/activation of the macrophage (74–76). HA of
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A B C
FIGURE 3 | The involvement of HA and CD44 in cell survival and
differentiation. (A) Model for the involvement of CD44v6 and Met due to
autocrine TGF β1 signaling in lung fibrogenic fibroblasts. The repetitive lung
injury in pulmonary fibrosis results in overexpression of TGFβ1 and
TGFβ1-induced autocrine signaling that induces a sustained expression of
CD44v6 and its co-receptor c-Met. This activates fibrogenic lung fibroblasts
with subsequent increased collagen matrix synthesis. Therefore, TGF
β1-induced CD44v6 and Met can have a crucial role for the sustained
fibrogenic activation of lung fibroblasts. The CD44-phosphorylated ERM
complex initiates activation of transforming growth factor-β receptor 1 and 2
(TGFβRI and II) and the downstream SMAD signaling complex, which
contribute to fibrosis. (B) Model for involvement of periostin in
HA-CD44-mediated cell survival and differentiation. Matricellular protein
[periostin (PN)] binding to β1 or β3-integrin activates FAK, which activates
downstream MAPK/Erk and PI3K/Akt to regulate cardiac valve cell growth,
survival, differentiation into fibroblasts, and matrix organization (maturation).
PN binding to β3-integrin also activates Has2 mRNA expression, Has2
phosphorylation, and HA synthesis. The interaction of HA with CD44, may, in
turn, amplify the downstream effects of PN on heart valve cushion cell
differentiation/maturation processes. (C) Cleavage of the extracellular
domain is accompanied by the cleavage of the intracellular domain (ICD) by
the presenilin-γ-secretase complex. The CD44 ICD acts together with CBP
or p300 as a transcription factor and promotes CD44 transcription and
extracellular matrix production.
size <5 105 Da (~250,000Da) induce inflammatory genes with
renal tubular epithelial cells (77), T-24 carcinoma cells (78), and
eosinophils (79). Similarly, HA fragments of size 8–16 disac-
charides induce angiogenesis in a chick corneal assay, whereas
the native HA molecules do not (80–82). Similarly, smaller HA
fragments in the 6–20 kDa size range induce inflammatory gene
expression in dendritic cells (83). Studies have shown that HA
of 40–400 kDa interact with HA-receptors to activate the NFκB-
mediated gene expression for endocytosis (84).Under certain con-
ditions, HA fragments (20–200 kDa size) function as endogenous
danger signals, while even smaller HA fragments (~2,500 kDa)
can ameliorate these effects in cancer (37, 85, 86). Thus, gener-
ation of HA fragments by HYALs (87) or by free radicals (88)
during inflammation/tumorigenesis/tissue injury send the signals
to the injured host that normal HA homeostasis is disturbed
due to activation of different signal transduction pathways. The
biological function of various sizes of HA is presented in Table 1.
Both physiological and pathological functions of HA are medi-
ated bymolecular interactionswithCD44 andRHAMMand other
HA-binding proteins (42). HA-rich glycocalyces anchored on cell
surfaces by CD44 and RHAMM can activate intracellular signal-
ing pathways (6, 42, 89), which can induce gene expression related
to cell–cell adhesion, cell spatial orientation and trafficking, cell
growth and differentiation, inflammation (11), wound healing
and tissue remodeling (11, 80, 90), tissue morphogenesis (11, 91)
matrix organization, and many inflammatory pathologies (6, 7,
19, 33–37, 92–100).
HA in Inflammation
The cell microenvironment has an important role in control-
ling inflammation. Prolonged inflammation leads to an influx of
inflammatory cells, and it is increasingly clear that ECM degra-
dation products are not only the result of inflammation but also
can perpetuate inflammatory processes. LMW HA interactions
with CD44 are associated with certain pathological conditions,
including inflammation, cancer, and induction of angiogenesis
(23, 33, 101–103).
Hyaluronan chains can be organized into ECM structures by
association with binding proteins. For example, HA cross-linking
is essential to stabilize the cumulus-oocyte complex and is needed
for successful ovulation and fertilization. The same mechanisms
are likely to occur at sites of inflammation, where HA synthesis is
upregulated (104, 105). Importantly, HA complexes of indetermi-
nate sizes originate from the surface of multiple cells and can be
coalesced into cable-like structures or HA fibrils at sites of tissue
inflammation, viral infection, endoplasmic reticulum (ER) stress,
and hyperglycemia. Monocytes/macrophages adhere to these HA
inflammatory matrices and fragment them by a mechanism that
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TABLE 1 | Various sizes of HA and their function in health and disease.
Sizes (kDa, or disachharide) Function of HA References
HA size >106Da Space-filling, providing structural frameworks for cells, functions as an extracellular molecule transmitting
signals, and regulates a variety of cell behaviors, including cell adhesion, motility, and growth
(6, 8–11, 37)
HA size >106Da Rapid matrix remodeling that occurs during embryonic morphogenesis, as well as tumorigenesis (4–7, 27, 37, 63–69)
HA size >~20MDa Ovulation, embryogenesis, wound repair, and tissue regeneration (62)
HA size >106Da Tyrosine kinase in endothelial cells and Ras-transformed fibroblasts at lower level (70, 71)
Extremely HMW HA (five times
larger than human HA)
Cancer resistance and longevity of naked mole rat (72, 73)
Excessive HMW HA production Inhibit tumor growth, possibly by suppressing cell–cell interactions, or ligand access to cell surface receptors
HA size <5 I05 Da Cytokine and chemokine production for differentiation/activation of the macrophage (74–76)
HA size ~250,000 Induces inflammatory genes in renal tubular epithelial cells, T-24 carcinoma cells, and in eosinophils (77–79)
HA size 8–16 disaccharides
(~3200–6400Da)
Induce angiogenesis in a chick corneal assay whereas the native HA molecules do not (80–82)
HA size ~6–20 kDa Induce inflammatory gene expression in dendritic cells (83)
HA of 40–400 kDa NFkB-mediated gene expression for endocytosis (84)
HA size ~2,500Da Upregulation of PTEN in tumor cells, and inhibit anchorage-independent growth as well as xenograft tumor
growth
(37, 86)
involves cell surface HYAL2 and CD44, which forms a cap on the
surfacewhile a portion of theHAmatrix is internalized. Therefore,
HA cross-linking represents an important new pathway in the
regulation of inflammatory processes (33, 105–110).
One of the functions of HMWHA is to maintain water home-
ostasis and matrix structure (111). However, during inflamma-
tion, there is increased breakdown of HMW HA by HYALs
(62), resulting in the accumulation of LMW forms that have
different functions than their HMW precursors (101, 112) (see
Figure 1). LMWHA is a potent activator of macrophages and air-
way epithelial cells (113–115). Specifically, LMWHA (~200 kDa)
can induce the expression of proinflammatory genes, such as
macrophage inflammatory protein (MIP), keratinocyte chemoat-
tractant (KC), macrophage chemoattractant protein-1 (MCP-1),
and IFN induced protein-10, as well as cytokines, such as IL-
8, IL-12, and TNF-α (76, 101, 112, 115–117). HA-stimulation
of macrophages is associated with matrix-modifying enzymes
(MMEs), inducible nitric oxide synthase (iNOS), and plasmino-
gen activator inhibitor (74, 116, 118). In addition, HA is also
depolymerized by ROS, and the HA fragments are implicated
in chronic inflammation (119). These HA-induced inflamma-
tory mediators can enhance the inflammatory response that has
already been set in motion, sending the system into a positive-
feedback loop where inflammation promotes further inflamma-
tion, which, if unchecked, may eventually lead to fibrosis.
HA in Cancer
There is a complex cross-talk between cancer cells and their
microenvironment. Strong evidence indicates that the tumor
microenvironment can regulate the capacity of tumors to grow
and metastasize (120). HA not only provides a cellular support
and hydrophilic matrix but also regulates cell–cell adhesion, cell
migration, growth, and differentiation (11). These properties
make it a suitable candidate for involvement in pathological
processes such as cancer. Furthermore, by forming pericellu-
lar coats, HA can protect tumor cells from immune attack (43,
44). Several tumor cells produce increased amounts of HA or
induce the production of HA by the release of growth factors and
cytokines. Such signals can regulate both HAS1, 3 and HYAL1.
Similarly, ROS-induced fragmented HA also contributes to over-
production of HA (54). Likewise, both tumor cells and stro-
mal cells express HAS isoforms and produce HA ECM, which
then accumulates in tumor parenchyma and in the peritumor
stromal tissues, which contributes to metastatic spreading (121–
125). Moreover, HA overproduction in tumor cells may induce
EMT-like epithelial changes of cancer cells toward a migratory
fibroblastic phenotype (126). HA-rich ECMmay also mediate the
recruitment of mesenchymal stem cells, which are progenitors of
tumor-associated fibroblasts (127).
In addition, HAS1–3 synthesize HA of dissimilar sizes, which
are linked to specific HA functions in wound injury (37, 125,
128–131) as seen in keratinocyte wound repairs, and during
mechanical injury in mesothelial cells (73, 132–136). Increased
production of HA in non-malignant cells impairs contact
inhibition of cell growth and migration (137). Likewise, forced
expression of HAS2 and HAS3 genes results in HA overproduc-
tion, which enhances the tumor forming ability of fibrosarcomas
and melanoma cells (67, 68) while abrogation of HAS2 blocks
xenograft prostate tumor growth (69). Transgenic mouse models
have shown that tumor-derived HA induces stromal reactions
with subsequent promotion of tumor angiogenesis and lymphatic
penetration within intratumoral stromal compartments (126).
In addition, HA-rich tumor-associated micro-environments
also accelerate the recruitment of inflammatory cells and the
production of cytokines and chemokines, and the HA fragments
generated by the degradation of HA can stimulate tumor growth
and angiogenesis (82). Thus, targeting HA-tumor cell receptor
interactions may identify promising therapeutic approaches in
cancer treatment. In addition to interaction with cell surface
receptors that initiate signaling pathways that impair vascular
function (138), HA can increase interstitial fluid pressure and
form a physical barrier against movement of small molecule
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therapeutics especially in pancreatic ductal adenocarcinomas
(61). Thus, depolymerizing HAwith HYALmay improve vascular
function and ease movement of therapeutics.
Interaction of CD44 and RHAMM with HA
Biology of CD44
CD44 is a broadly distributed cell surface glycoprotein found on
hematopoietic cells, fibroblasts, and numerous tumor cells. It was
first identified as gp85 (14) and was then shown to be a HA-
receptor in placenta cells when their adherence to immobilized
HA was inhibited by an anti-CD44 monoclonal antibody, by
soluble HA, and by HYAL (16, 139–142). However, the presence
of the amino-terminal HA-binding region of CD44 does not
guarantee that cells expressing CD44 will bind HA. Indeed, most
CD44-expressing cells taken from normal animals, as well as from
CD44+ cell lines, do not bind HA. Binding of CD44 to HA is cell
specific and depends on the activation state of CD44 (143). CD44
has seven extracellular domains, a transmembrane domain, and a
cytoplasmic domain (Figure 2) (144). The extracellular structure
has two regions (amino acids 21–45 and amino acids 144–167)
that contain clusters of conserved basic residues that have been
implicated in HA binding, the BX7B motif. This motif, which
is found in other HA-binding proteins, including RHAMM, is
present as a single copy in the first of these regions, and as an over-
lapping pair in the second region (Figure 2). The pairs of intra-
molecular disulfide bonds are also crucial for HA-binding activity.
The HA-binding domain located in the amino-terminal region is
present in all isoforms (145). The membrane proximal region is
less well conserved and contains the insertion site for the variant
exon domains. The transmembrane and C-terminal cytoplasmic
domains are highly conserved (142, 146, 147) (Figure 2).
CD44 is encoded by a single gene. Due to alternative splicing,
multiple forms of CD44v are generated that are further modified
by N- and O-linked glycosylation. The smallest CD44 standard
isoform (CD44s) lacks variant exons, contains an N-terminal
signal sequence (exon 1), a link module that binds to HA (exons
2 and 3), a stem region (exons 4, 5, 16, and 17), a single-pass
transmembrane domain (exon 18), and a cytoplasmic domain
(exon 20). In all forms of CD44 cDNAs, exon 19 is spliced out so
that the transmembrane domain encoded by exon 18 is followed
by the cytoplasmic domain encoded by exon 20, producing the 73
amino acid cytoplasmic domain. CD44s is found in most cells (6),
whereas the isoforms that contain a variable number of exon inser-
tions (v1–v10) at the proximal plasma membrane external region
are expressed primarily on cells during inflammation and on
tumor cells (24, 28, 65, 94) (Figure 2). More importantly, variants
of CD44, specifically CD44v6, promote tumor progression and
metastatic potential in lung, breast, and colon cancer (6, 24, 94, 95,
148, 149). Subsequently, several tumors, including colon cancer
(150–154), Hodgkins lymphoma (155), gastric cancer (156), and
melanoma (157), have been screened for CD44 isoforms, indi-
cating that certain CD44 variants have crucial roles for tumor
progression. HA and CD44s are present on themembrane of most
vertebrate cells (65).
CD44 is a multifunctional receptor having diverse roles in
cell–cell and cell–matrix interactions such as cell traffic, lymph
node homing, prothymocyte homing, lymphocyte activation, cell
aggregation, releasing chemokines and growth factors, and pre-
senting them to traveling cells (158, 159). CD44 can be a pro-
teoglycan with a potential chondroitin sulfate (CS) or dermatan
sulfate (DS) substitution. Insertion of the v3 exon also includes the
potential for heparan sulfate (HS) chain substitution (24), which
can influence ligand binding and cell behavior by allowing CD44
to be a co-receptor for hepatocyte growth factor (HGF)with c-Met
(160). The affinity of CD44 for these GAG substitutions depends
on posttranslational modifications, such as oligosaccharide and
GAG addition (161–163), and their subsequent functions depend
on cell types and growth conditions (6, 24). These modifications
can be altered by physiological stimuli, resulting in the induction
ofHAbinding. In the immune system,HAbinding can be induced
in T cells upon antigen recognition (164) and upon monocyte
activation by inflammatory stimuli (51, 52, 147). Unlike HAS2
deficient mice (19), CD44-null mice develop normally, indicating
that CD44 is dispensable for development (53).
In addition to binding to HA, CD44 can interact with sev-
eral ECM proteins, including fibronectin, collagens, growth fac-
tors, cytokines and chemokines, and matrix metalloproteinases
(MMPs) (6, 24, 26). To contribute to pericellular proteolysis, CD44
facilitates activation of MMP-9 on the surface of carcinoma cells
(165). CD44-mediated localization of MMP-9 on tumor cells can
regulate tumor cell motility, growth factor activation, and survival
mechanisms. It can also activate latent TGFβ and promote tumor
invasion and angiogenesis (166) (Figure 3A). Tumor growth and
metastasis is associated with increased levels of soluble CD44 (sol-
CD44), which is detected in plasma from cancer patients (167),
indicating increased proteolytic activity andmatrix remodeling by
CD44. Sol-CD44 is likely to affect cellular behavior by perturb-
ing HA-CD44 interactions by acting as a sink for HA and may
regulate cell migration by disrupting CD44-dependent cell–cell
and cell–matrix adhesion. Cleavage of the extracellular domain
of CD44 can be followed by subsequent proteolysis within the
transmembrane domain and subsequent liberation of the CD44
intracellular domain (ICD) (168). The ICD can then translocate
to the nucleus and promote transcription of CD44, providing
a feedback mechanism for regulating CD44 expression (169)
(Figure 3C).
Decades of research have shown that CD44 participates in
major oncogenic signaling networks and in complexes with onco-
genes that promote every aspect of tumor progression (6, 24).
CD44 is extremely sensitive to changes in the microenvironment.
For example, CD44 in breast cancer cells may act as a metastatic
suppressor gene when influenced by ROS, as seen by decreased
CD44 protein expression in the malignant and tumorigenic breast
cancer alpha 5 cell line in a compensatory response to increased
manganese superoxide dismutase (MnSOD) protein expression
(170). Studies by Stoop et al. (171) showed that the cancer-
initiating function in CD44-null mice was less severe, whereas
the inflammatory functions were persistent in these mice sug-
gesting again the possibility of a molecular redundancy in this
model. Many of the contradictory findings published to date
may be due to experimental and technical differences among
studies. However, a picture has emerged suggesting that CD44
may function differently at different stages of cancer progres-
sion (172, 173). For example, mice with germline disruptions of
CD44 display relatively mild phenotypes compared with mice in
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which tissue-specific CD44 function is disrupted at adult phases
of development, or in later phases. This suggests that the absence
of CD44 in early development and a loss of CD44 function late
in development are tolerated differently (24). As CD44 is the
major HA-receptor and a co-receptor for EGF, it was surprising
to find that CD44-null mice had a mild phenotype. However,
roles for this molecule in the immune system were revealed by a
bacterial pneumonia model in which the null mice had enhanced
edema and lung neutrophil accumulation (174). Therefore, CD44
appears to have a role in limiting inflammatory responses, which
has also been shown in inflammation models (24).
Unlike CD44s, CD44v variants are only expressed on some
epithelial cells during embryonic development, during lympho-
cyte maturation and activation, and in several types of carcinomas
(175). In particular, upregulation of CD44v6 is an early event in
carcinogenesis and requires adenomatous polyposis gene inacti-
vation (153, 176, 177). We found that overexpression of HAS2 in
pre-neoplastic Apc10.1 cells induces CD44v6 expression, and the
intestinal/colon tumors of Apc1 Min/+ mice express CD44v6 at
substantially higher levels compared to expression of CD44s (94).
A considerable number of studies indicate that CD44 variant iso-
forms correlate with bad prognosis in patients with most human
cancers (151, 178–184) except in neuroblastomas and prostate
cancer (185, 186). CD44v6 is quite likely to be a suitable target for
anticancer therapy because it is: (a) causally involved inmetastasis
of a rat pancreatic carcinoma (187); (b) redundantly correlates
with the human tumors mentioned above; and (c) correlates with
oncogenic functions in colorectal cancer (CRC) both in vitro and
in vivo (6, 94, 178, 180, 181, 188).
CD44 in Inflammation
The role of CD44 in the immune system was first found when
immune responses were examined using monoclonal CD44
antibodies (mAbs) in wild type mice. KM201 blocked HA-
CD44 interaction, whereas IRAWB14 enhanced HA binding. IM7
induced the shedding of CD44 from the cell surface and induced
neutrophil depletion (189–192), indicating that in addition to
blocking HA-CD44 interaction, CD44 mAbs can also alter HA-
independent functions, such as interactions of CD44 and E- or
L-selectin. These approaches support a proinflammatory role for
CD44 (193, 194).
Other studies show that leukocyte rolling on inflamed endothe-
lium is not onlymediated by the selectinmolecules, but can also be
mediated by the interaction of T cell CD44 with HA on activated
microvascular endothelial cells (195, 196). Moreover, CD44 and
HA can facilitate the recruitment of neutrophils to sites of inflam-
mation in some instances (197–199). Reduced recruitment of
CD44-null macrophages to atherosclerotic lesions (200) indicates
the contribution of CD44 to monocyte/macrophage recruitment
to inflammation sites. CD44-null mice also experienced reduced
levels of cerebral ischemia injury, further supporting a proin-
flammatory role for CD44 (201, 202). Studies also revealed that
treatment with anti-CD44 mAbs reduced the severity of arthri-
tis in a collagen-induced mouse model for human rheumatoid
arthritis (RA) (203–205) and reduced the diabetic activity inNOD
nice (206). The decrease in disease severity was associated with
the delayed access of donor lymphocytes into the RA joints of
recipient animals (171, 207). In human RA, CD44v5, CD44v6,
and CD44v10 have been detected in synovial fluid and serum
of patients (208, 209). In an inflammatory bowel disease (IBD)
model, expression of CD44v7 is crucial for colonic inflammation
(210, 211). Furthermore, CD44v6 expression is associated with
IBD severity in patients (212–214). Extensive HAmatrix accumu-
lates in bleomycin-induced lung fibrosis in CD44-null mice with
persistent lung inflammation, extended chemokine production,
impaired clearance of apoptotic lymphocytes, and death (215).
Our recent study showed that a feedback loop between CD44v6
and TGFβ1 augments the fibrogenic functions of lung fibroblasts
in interstitial lung disease (92). In this study, we showed that
TGFβ promotes c-Met expression and CD44v6 expression that
is accompanied by the CD44v6-induced formation of α-SMA,
increased cell proliferation and collagen production (Figure 3A).
The CD44v6 signaling complex with TGFβRI and TGFβRII stim-
ulates downstream SMAD signaling (Figure 3A). These find-
ings provide clear evidence that TGFβI initiates the signaling
cascade through CD44v6 toward differentiation of fibroblasts to
myofibroblasts (92). They do not exclude a further contribution
of CD44v6 by activating the TGFβ1 proform through associ-
ated MMPs (166, 216). Overall, these studies indicate the critical
involvement of CD44 and its variants in a number of inflamma-
tory situations. However, the specific role of CD44 depends on the
model system and the disease.
CD44 in Cancer
Although studies in vitro indicate that the tumor promoting func-
tion ofHApartly depends on itsmolecularweight (37, 86, 99, 217),
and on its capacity to interact with other proteins (26, 218), many
of the tumor promoting activities of HA could be explained by
its interaction with CD44. There are three ways how CD44 can
interact with HA.
CD44 Binds to Soluble Extracellular HA Molecules
and ECM
CD44 proteins exist in three states with respect to HA binding:
non-binding, non-binding unless activated by physiological stim-
uli, and constitutive binding (140, 219, 220). CD44 is endoge-
nously expressed at low levels on various cell types in normal
tissues (169), but it requires activation before it can bind to HA.
Importantly, the minimal size of HA fragments binding to CD44
are six monosaccharide units (HA6). Thus, HMW HA in the
ECM degraded by HYALs into smaller fragments can still bind
to CD44 (221). Activated CD44 is overexpressed in solid tumors,
butmuch less, or not at all on their non-tumorigenic counterparts.
Adhesion of CD44 to HA induces upregulation of integrins that
strengthen stem cell adhesion (222). Cross-talk between CD44
and CXCR4 signaling is a key role for HA and CD44 in CXCL12-
dependent trans endothelial migration of stem cells (223). Tumor-
derived cells express CD44 in a high-affinity state that is capable
of binding and internalizing HA. Transitions from the inactive,
low-affinity state to the active, high-affinity state by CD44 require
posttranslational modifications, i.e., glycosylation in the extracel-
lular domain and/or phosphorylation of specific serine residues
in the cytoplasmic domain (26, 161) Such modulation of binding
affinity of CD44 with HA is important for cellular migration that
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enables CD44 to be incorporated into the leading edge of the cells
and lamellipodia (224).
CD44 can also react with other molecules, including collagen,
fibronectin, osteopontin, growth factors (24), andMMPs in tumor
cells (167, 225), but the functional roles of such interactions are
less well known (24). Inhibiting cleavage of CD44 inhibits tumor
cell migration on a HA substrate, suggesting that CD44 cleavage
could release cells bound to a HA ECM (24). CD44 can also
influence adhesion and de-adhesion to the ECM by regulating the
pericellular HA matrix metabolism (226).
CD44 Interacts with Receptor Tyrosine Kinases for
Anti-Apoptosis and Drug Resistance
Receptor tyrosine kinases (RTKs) are a subclass of cell surface
growth factor receptors (GFRs) with an intrinsic, ligand-
controlled tyrosine kinase activity (227). The cytoplasmic
domains of RTKs contain catalytic kinase activity and
phosphorylation motifs that on activated RTKs assemble many
intracellular signaling molecules. Apart from their activation
by the auto phosphorylation of cytoplasmic subunits of RTKs,
they are also activated by their association with several proteins,
which are known as co-receptors of RTKs. These co-receptors do
not have kinase activity, but they modulate the kinase activity
of RTKs.
HA-CD44 or HA-CD44v interaction has a general effect on
activation of cell survival anti-apoptotic proteins, which is initi-
ated through the association with RTK activation. In malignant
colon, prostate, and breast carcinoma cells, HA-CD44 interac-
tion activates multiple RTKs, including ERBB2, ErbB3, EGFR,
IGF1R-β, PDGFR-β, and c-MET, as well as assembly of lipid-raft-
integrated signaling complexes containing these activated RTKs,
CD44, ezrin, PI3-kinase (PI3K) and the chaperone molecules
HSP90 and CDC37, which strongly promotes apoptosis resistance
in cancer cells (94, 96, 149, 228–231). Increased HA production,
however, induces RTK activation and signaling complex assembly
in phenotypically normal epithelial cells (96). These macromolec-
ular signaling complexes of CD44 also contain RhoA-specific
guanine nucleotide exchange factor (p115RhoGEF), which is
upstream of Grb2-associated Ras and PI3-kinase (98) and VAV2,
which regulates cytoskeletal reorganization through RAC1 acti-
vation (232) (Figure 4A). A blockade of the HA-CD44 interaction
causesmacromolecular lipid-raft-integrated complex disassembly
and inactivation of RTKs in various cancer cells including breast,
colon, and prostate cancer (6, 19, 93, 96, 188, 228–231). CD44
also associates with non-RTKs, such as SRC, which has a central
role by linking various extracellular signals to crucial intracellular
signaling pathways (233). Thus, the lipid-raft location of CD44
is of particular importance for the involvement of CD44 in cell
motility and signal transduction and accounts for the CD44-HA-
binding-initiated cross-talk between RTKs, non-RTKs, and linker
proteins (234, 235). In colon cancer, the HA-CD44v6 interaction
and recruitment of ERBB2 also induces the transcription of COX2
initiated downstream of CD44 through PI3K-Akt and β-catenin
(93, 188). COX2 further strengthens apoptosis resistance and
HA-CD44 interaction through prostaglandin E2 expression (93,
188) (Figure 4B). CD44v6 also initiates MET activation through
HGF binding. This requires the cytoplasmic tail of CD44 and the
interaction with ezrin, radixin, and moesin (ERM) proteins for
activation of the Ras-MAPK pathway (236). In addition, CD44v6
binding to the ECM also activates the PI3K-Akt pathway (237,
238) (Figure 4B) and regulatesMet transcription (239).
Hyaluronan-CD44 cross-linking regulates drug transporter
expression (228, 240–242). In addition, a positive-feedback loop,
involving HA, PI3K, and ErbB2, augments MDR1 expression and
regulates drug resistance in breast cancer cells (228) (Figure 4A).
MDR1 is associated with CD44 in lipid microdomain and can
be linked via CD44 with the actin cytoskeleton so that expres-
sion of both CD44 and MDR1 are concomitantly regulated (240)
(Figure 4A). HA-CD44 binding promotes protein kinase Cε
(PKCε) activation, and this increases NANOG phosphorylation
and translocation to the nucleus (243). These events initiate the
upregulation of MDR1, and then CD44 can associate with and
stabilize MDR1 gene expression (244). In contrast, pro-metastatic
miR-373-520c downregulates CD44 (245) indicating that onco-
genic miRNAs can regulate CD44 cell behavior in a specific way.
CD44 Can Act as Co-receptor
CD44v6 can function as co-receptor for RTKs and alter the activa-
tion of GFR kinases. The CD44v segments contain some specific
posttranslational modifications that include HS on a site in exon
v3, which can bind proteins such as fibroblast growth factor 2
(FGF2). Such a function is not confined to HS-modified CD44v3
isoforms. It can also be provided by CD44v6 isoforms, which act
as co-receptors, i.e., CD44v6 contains a binding site for RTKs,
HGF receptor c-Met, vascular endothelial growth factor (VEGF)
receptor VEGFR-2, proteins involved in cancer, and in fibrosis
(92, 103, 236, 246, 247). Thus, HA interactions with CD44v can
have a central role in RTK activated cell pathways that promote
tumorigenic functions, including cell survival, through the RTK
activation and consequent MDR1 gene activation. Importantly,
activation of signaling pathways initiated by HA-CD44v interac-
tions in the tumor matrix can be inhibited by HA degradation,
by inhibiting HA binding to CD44v with small HA fragments, by
blocking the CD44v HA-binding site, or by CD44v knockdown
(6, 94, 95, 248). Further, blockade of an individual RTK does not
recapitulate all of the effects observed when HA-CD44v interac-
tion is inhibited (149). HYAL, as well as low molecular mass HA
oligosaccharides (oHAs), also improves drug efficacy (228, 241)
and drug transporter expression (228, 242, 249) (Figure 8).
Binding of CD44 to Actin Cytoskeleton
CD44 and its associations with partner molecules, such as
ERM proteins, participate in CD44-induced cell survival signal-
ing, altered cell shape, and protein localization to the plasma
membrane subdomains during cell migration (250). Ankyrin is
involved in HA-CD44 dependent cell adhesion and motility. This
involves binding of the N terminus of activated ERM to a motif
between the transmembrane region and the ankyrin-binding site
in the cytoplasmic domain of CD44, and subsequent binding
of their carboxyl termini to filamentous actin (F-actin). This
binds CD44 to cytoskeletal linker proteins, and this interaction is
modulated by HA-CD44 interaction (251, 252). Overexpression
of merlin, another member of the ERM family, inhibits subcu-
taneous growth of Tr6BC1 cells in immunocompromised Rag1
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A
B
FIGURE 4 | CD44- and CD44v-induced RTK for apoptosis resistance.
(A) CD44-HA binding, accompanied by activation of CD44-associated SRC,
ezrin phosphorylation, and PI3K activation leads to the lipid-raft-integrated
assembly of a complex that includes heat shock protein 70 (HSP70), the
co-chaperone CDC37, Rho-GEF, Grb2/VAV2, and Gab-1/PI3-kinase (PI3K),
which promotes phosphorylation and activation of the receptor tyrosine kinases
(RTKs), including ERBB2, ErbB3, EGFR, IGF1R-β, PDGFR-β, and c-MET.
CD44-HA binding initiates cross-talk between RTKs, non-RTKs [SRC (Src)] and
linker proteins. Studies have indicated that ErbB2 most likely complexes with
CD44 via interactions with Grb2 and Vav2, whereas the interaction of PI3K and
CD44 is mediated by Gab-1. PI3K activates Akt and downstream anti-apoptotic
events, which contribute to drug resistance. However, HA and PI3K stimulate
MDR1 expression, and the stimulatory effects of PI3K would be mainly due to its
feedback stimulation of HA production by a positive feedback loop. Studies
indicate that MDR1 is associated with CD44 in lipid microdomain and can be
linked via CD44 with the actin cytoskeleton so that expression of both CD44
and MDR1 are concomitantly regulated. (B) Particularly, in colorectal cancer, the
CD44–ERBB2 complex provides a strong apoptotic resistance through
stimulation of cyclooxygenase 2 (COX2) transcription via PI3K and β-catenin.
COX2-induced PGE2 stimulates HA synthesis and HA-CD44 signaling. CD44v6
also binds hepatocyte growth factor (HGF) and presents it to c-MET. Activation
of MET and the downstream signaling cascades require sustained activation of
CD44-associated phosphorylated ezrin, radixin, and moesin (ERM) and SRC
(Src) signaling via the Ras-MAPK and the PI3K-Akt pathway. Ras-Erk pathway
can augment CD44v6 synthesis through a feedback loop between CD44v6 and
c-Met/Ras-Erk pathway.
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mice by negatively regulating CD44 function. In contrast, knock-
ing down expression of endogenous merlin promoted tumor cell
growth (253, 254).
Biology of RHAMM
Receptor for HA-mediated motility, an acidic and coiled-coil pro-
tein designated as CD168 (20), was first identified as a component
of the HA-receptor complex in the conditioned media of murine
fibroblasts (21, 22). It is located intracellularly in the cytoplasm,
in the nucleus, and on the cell surface (255). There is no link
module domain in RHAMM, but it includes a HA-binding region
through the BX7B motif on its COOH terminus (27). RHAMM
lacks a transmembrane domain but is GPI-anchored to the cell
membrane, where it can interact with CD44 and participate in
many cell functions, including cell motility, wound healing, and
modification of signal transduction of the Ras signaling cascade
(28, 256–259). Surprisingly, RHAMM contains no signal peptide
and is thought to be transported to the cell surface via uncon-
ventional transport mechanisms, where it associates with the cell
surface via docking with HA synthase (260), and like CD44, it
transduces signals that influence cell motility (28, 30).
RHAMM Signaling in Inflammation and Cancer
Extracellular RHAMM interacts with protein tyrosine kinase
receptors (RTKs) and non-protein-TK receptors, including
PDGFR (29), TGFβ receptor-1 (261), CD44 (259, 262), CD44-
EGFR complexes (263, 264), bFGFR (265), and RON (266).
These extracellular interactions can mediate motility necessary
for inflammation through activation of ERK1/2/MAPK in
the absence of intracellular RHAMM. Extracellular RHAMM
can regulate cellular transformation and migration in an HA-
dependent manner. It can bind to CD44 on mesenchymal cells
in wounds, which is necessary for the sustained activation and
nuclear translocation of activated ERK1, 2, and for cell migration
with increased mesenchymal differentiation within wound
sites (259, 267).
Intracellular RHAMMbinds to both actin filaments andmicro-
tubules in the cytoskeleton, in addition to interacting with ERK
and SRC kinases (30, 268). Moreover, intracellular RHAMM
also binds to a number of proteins, which can regulate micro-
tubule dynamics and centrosome structure/function through
ERK1/2/MAP kinase activation that contributes to microtubule-
mediated cell polarity and cell migration. Nuclear RHAMM also
binds to ERK1/2/MAP kinase, which mediates activation of PAI-
1 and MMP-9 that are involved in cell motility and inflam-
mation (132) (Figure 5). Secreted RHAMM can bind HA and,
in concert with CD44, augment invasiveness in breast cancer.
These interactions suggest that RHAMM may be necessary for
CD44-mediated migration during inflammation, wound heal-
ing, tumorigenesis, and regulation of stemness/EMT phenotypes
within tumor-initiating populations (256, 269, 270). Intracellular
RHAMM, both cytoplasmic and nuclear, interacts with several
signaling proteins and cytoskeletal components, including SRC,
ERK1, actin, and microtubules (28, 29, 271). RHAMM regulates
mitotic organization of microtubules through cytoskeletal ele-
ments aurora kinase A (AURKA), and BRCA1 (267, 272, 273),
which is crucial for cellular fates, such as luminal differentiation
and EMT. In addition, disruption of AURKA (274), BRCA1 (275),
or RHAMM (276) modifies neurite extension, an alternate dif-
ferentiation program dependent on microtubule nucleation (267)
(Figure 5).
Biology of HA-CD44/RHAMM Interaction
Given the crucial role that HA has in cancer cell survival, pro-
liferation, and invasion, it is clear that HA interactions with
both CD44 and RHAMM can induce numerous cell behaviors,
including activation of tyrosine kinases, protein kinase C, FAK,
and PI3K, MAPK, NFκB, and RAS, as well as cytoskeletal com-
ponents required for inflammation and cancer (6, 24, 28, 132,
277) (model in Figure 5). While CD44 and RHAMM can interact
independently with HA to induce cell behavior, in some cases
their relative contributions result in redundant and overlapping
functions. For example, in a collagen-induced model of arthritis,
inhibiting CD44 function attenuates the disease, indicating the
involvement of CD44 (193). RHAMM is significantly elevated in
the knee synovial tissue of patients with advanced osteoarthritis
compared to those without (278). These results are consistent with
animal model studies demonstrating an isoform-specific role for
RHAMM in collagen-induced arthritis (193). The findings from
Nedvetzki et al. (193) indicate that arthritis in WT mice is CD44
dependent, whereas in CD44-knockout mice, it is RHAMM-
dependent, as determined by antibody blocking and soluble pep-
tide competition studies. This suggests that CD44 and RHAMM
coexist inWTmice, but cell surfaceCD44 functions are dominant.
Cell surface CD44may primarily influence the joint inflammatory
cascade in WT mice by its ability to quantitatively compete with
cell surface RHAMM for HA and/or by its ability to regulate the
potency of RHAMM-mediated signaling that may or may not be
HA dependent. Absence of CD44 exacerbates bleomycin-induced
lung inflammation in CD44-null mice due to accumulation of
extensive HA ECM (215). In light of Nedvetzki’s findings (193),
the augmented lung inflammation/fibrosis in bleomycin-induced
CD44-null mice (215) may be due to RHAMM (193). Further, HA
accumulation was greater in the arthritic joints of CD44-deficient
mice than in those of wild type mice where CD44 (but not
RHAMM)promotes endocytosis ofHA and its subsequent lysoso-
mal digestion. The excess HA in CD44-null mice may contribute
to prolonged signaling through RHAMM (28), which might lead
to aggravation of the inflammatory lung fibrosis. Thus, the loss of
the CD44 gene could be compensated with enhanced expression
of RHAMM. Moreover, the loss of CD44 allows enhanced accu-
mulation of theHA in ECM,with which both CD44 and RHAMM
interact (193). In other words, this study indicates dual functions
of CD44 in arthritis, one that causes disease initiation and another
that limits disease severity, at least in part by reducing pathology
promoting effects of RHAMM (193).
Similarly, in RHAMM null fibroblasts, migration is impaired
due to reduced CD44 at the cell surface, and to impaired ERK1
activation and impaired wound healing (259). Interestingly, the
dual functions of CD44 exist in cancer where tissue-specific
expression of specific variant isoforms of CD44v appears to con-
trol progression of some cancers (6, 94, 95), and these isoforms
regulate tumor-initiating cells in sub populations of cancer cells
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FIGURE 5 | Cross-talk between CD44 and RHAMM interaction with
HA affects physiological and cellular functions. Green Track is for
extracellular RHAMM signaling involving CD44-HA-mediated pathways. Red
track is for intracellular RHAMM signaling. Studies suggest a model for
functions of CD44 and RHAMM. The interaction of HA-CD44-RHAMM
affects physiological and cellular functions. Cell surface RHAMM interacts
with CD44, HA, and growth factor receptors (GFR) to activate protein
tyrosine kinase signaling cascades that activate the ERK1/2 MAP kinase
cascade in a c-Src/Raf-1/MEK-1/ERK1/2 dependent manner (depicted in
green track). In the absence of intracellular RHAMM, this signaling can
stimulate the transcription of motogenic effectors to regulate a mitogenic
response (cell proliferation/random motility). In the presence of intracellular
RHAMM (red track), MEK-1/p-Erk1/2 also binds to a number of protein
partners that allows activated RHAMM to enter the nucleus to regulate
functions of microtubule dynamics via centrosome structure/function, and
cell cycle progression via AURKA, a targeting protein for XkIp2 (TPX2).
Activated RHAMM also controls expression of genes involved in cell motility
such as PAI-1 and MMP-9.
(149). Similarly, overexpression of RHAMM controls severity of
carcinogenesis (e.g., breast cancer, CRC, multiple myeloma) (239,
255, 279), and loss of RHAMM regulates peripheral nerve sheath
tumor progression (280), suggesting duality of RHAMM perfor-
mance to maintain cell behavior. Studies also indicate that the
oncogenic role of RHAMM can be limited through the activa-
tion of p53 (281). Further, RHAMM and CD44v isoforms co-
existed in 65% of the cancer cases with another 23% having
either RHAMM or CD44v expression. Recent studies demon-
strated that RHAMM- and CD44-mediated cell adhesion and
motility appear reciprocal rather than overlapping (282), whereas
concurrent expression of CD44 and RHAMM genes might confer
tumorigenicity of gastric cancer cells (283).
This section has reviewed evidence for secretion of intracel-
lular regulators of mitosis and differentiation in the determina-
tion of cellular migration, tumorigenesis, and inflammation by
overlapping and independent interaction of CD44 and RHAMM
with HA (Figures 3–5). The presence and functions of these
multifunctional HA-receptors have been examined both in dis-
eased human tissues as well as in animal models of diseases.
The modulation of these receptors may dramatically alter disease
functions. The next section discusses the emerging cell-based
strategies to target these molecules in inflammatory diseases, and
particularly in cancer.
Therapeutic Approaches to Interrupt HA
Interaction with Receptors
The inexorable course of progressive inflammation is similar
in both the inflammatory diseases and in cancers. The semi-
nal properties of these inflammatory and cancer cells involve
cell adhesion, proliferation, migration, and invasion, and the
HA-CD44 interactions can regulate these processes. Due to the
unavailability of specific inhibitors, the physiological functions
of HA have been mostly deduced from the biological changes
caused by HA-receptor antagonists that can block the HA-CD44,
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TABLE 2 | HA-CD44-RHAMM function in inflammation and cancer.




Unremitting inflammation and death,
and accumulation of both HMW and
LMW HA
CD44 antibody (Ab) (295)
Excisional wound skin injury model Acute and chronic skin inflammation 12-mer Pep-1 peptide (132, 297, 306, 307)
P15-1 peptide
Staphlococcal aureus colonization of
incisional skin wounds
Increased accumulation of CXCL1,
CXCL2 and neutrophils after skin injury
Pep-35 (304, 305)
Bleomycin-induced lung injury mice
model
Inflammation and fibrosis in lung injury RHAMM (HABP) and RHAMM-like Peptide A (295)
Disease model Function of HA in cancer Experimental approach by using HA-drug carriers Reference
Bladder cancer G2–M arrest and apoptosis HYAL-1-v1 (312, 316–318)
Mitotic/oncogenic responses HA (~10-12kDa)-PTX conjugated drugs
EMT-6 tumor spheroids Increasing the accessibility to the
chemotherapeutic drugs
Bovine testicular or bacterial hyaluronidase (314)
Pancreatic ductal adenocarcinoma Reduction of metastasis Soluble form of PH20 (60, 61)
Colon, breast, esophageal, ovarian
prostate cancer
Mitotic/oncogenic characteristics HA (~200 kDa)-Irrinotecan conjugated drugs (320–322)
Bone disease in cancer Mitotic/oncogenic characteristics HA (~750 kDa)-5-FU, doxorubicin (323–325)
Colon cancer Mitotic/oncogenic characteristics HMW HA-bisphosphonate (326)
CD44 positive cancer Mitotic/oncogenic characteristics Nanoparticle delivery of chitosan-HMW HA (328–330)
CD44 positive cancer Mitotic/oncogenic characteristics Lipid-HMWHA-mitomycin C (HA-LIP) (332–336)
CD44 positive HNSCC Mitotic/oncogenic characteristics Micelles to deliver paclitaxol, doxorubicin, Salinomycin (338–340)
B16F10 murine melanoma and lung
carcinoma cells
Mitotic/oncogenic characteristics HA-nanocarrier to deliver doxorubicin, epirubicin (335, 341)
Melanoma and breast cancers Mitotic/oncogenic characteristics Paclitaxel, mitomycin C, and various nanoparticles (316, 341, 343–350)
and HA-RHAMM interactions. Here, we describe the possibility
for therapeutic approaches to interfere with HA-CD44-RHAMM
interactions (Table 2).
Role of HA, and HA-Receptors in Drug
Conjugates
The success of HA as a carrier depends on the number of receptors
available on the target cells and on the affinity between the homing
ligand and the receptor. HA preparations have been approved by
the Federal Drug Administration as a medical device.
HA-Preparations Used for
Non-Inflammatory/Non-Tumorigenic Therapies
(i) A transdermal drug delivery of insulin using micro needles
(MNs) fabricated with 15%HA containing insulin is used in
diabetes patients (284) (Table 2);
(ii) Transcutaneous immunization (TCI) of tetanus toxoid (TT)
and diphtheria toxoid (DT) uses mixtures of sodium
HA separately with TT and DT to form the MNs
(285–288);
(iii) Antibodies against TNF-α or IL-1β conjugated to HMW
HA diffuse slowly thus providing a sustained delivery of the
antibodies in the wound (84);
(iv) Intra-articular injections have been used for the treatment
of osteoarthritis of the knee, although further studies are
required to establish its efficacy (289, 290); and
(v) HA has been approved as a surgical aid in eye surgery (291)
and to improve skin elasticity (292).
Targeting HA and HA-Receptors in Anti-Inflammatory
Therapies Using HA-Binding Peptide
Recent investigations have taken advantage of the peptide-based
probes to develop imaging agents to target HA-binding regions of
HA-receptors (Table 2). HA, CD44, and RHAMM are known to
regulate immunity during tissue repair, including innate immune
cells such as macrophages, and fibrogenesis (26, 28, 65, 112,
116, 132, 192, 210, 215, 259, 293–300). Thus, it is likely that
HA-binding peptides can alter the HA-binding capacity of HA-
receptors and modify disease processes such as tissue fibrosis,
wound infection, contact hypersensitivity, and melanoma metas-
tases in experimental models (293, 301–304).
CD44 and HA have been targeted for anti-inflammatory ther-
apies using HA-binding peptides derived from a M13 phage-
display library. One of these, Pep-1, which is a specific 12-mer
HA-binding peptide, prevents leukocyte adhesion to HA (304)
and inhibits leukocyte recruitment during contact hypersensi-
tivity (304, 305). Pep-1 inhibits the binding of cells expressing
HA-receptors (e.g., CD44) to immobilized HA substrate as well
as the binding of soluble HA to cells expressing such receptors,
implying that Pep-1 and HA-receptors compete for binding to the
same ligand in acute skin inflammation (58). The peptide can
also inhibit interleukin-2 induced vascular leak syndrome inmice
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by reducing damage to the endothelium, although lymphocyte
migration was not affected (305). Pep-1 also inhibited secretion
of the proinflammatory chemokine MIP-2 from HA stimulated
macrophages (62). Studies on therapeutical aspects are currently
under investigation that include the inhibition of enzymes that
cleave CD44 (306) and CD44 vaccination (307), which provides
partial resistance to experimental autoimmune encephalomyeli-
tis (307). To date, no therapies have yet been developed that
focus on augmenting the function of CD44 in the resolution of
inflammation.
Using BLAST and ClustalX2, database searches between
RHAMMandmicrotubule binding domains inmicrotubule bind-
ing proteins revealed only a moderate sequence homology of
17–24% to the HA-binding domain of RHAMM (295). Among
the peptides, P15-1 preferentially binds oHAs (<10 kDa) with a
moderate affinity, and this peptide specifically mimics and blocks
HA-RHAMM-induced FAK signaling, resulting in the healing of
excisional wounds (132, 295). This peptide had no visible effect on
incisional skin injury repair, which is consistent with genetic dele-
tion of RHAMM, which affects excisional but not incisional skin
injury (259, 295, 308). Pep-35, which encodes two RHAMMHA-
binding sequences, also reduced Staphylococcus aureus coloniza-
tion of incisional wounds (302) by increasing the number of neu-
trophils and their expression of CXCL1 and CXCL2 after injury
(303). Short peptides of RHAMM [hydrazide group to bispho-
sphonate (HABP)] and RHAMM-like (peptide A) also reduced
inflammation and fibrosis in lung injury models by reduc-
ing macrophage migration and accumulation, and by reducing
hydroxyproline (collagen) content in the lungs of the bleomycin
injury mouse model (293). Similarly, RHAMM HA-binding pep-
tides inhibited arthritis formation in collagen-induced arthritis in
mice (193). These studies suggest that blocking HA-RHAMM, or
HA-CD44 interactions could have therapeutic benefits in inflam-
mation and wound repair disease processes in light of the dual
roles of CD44 in the inflammatory response as discussed above
(202, 216, 309) in specific diseases.
HA-Drug Conjugates in Cancer
Enzymatic degradation based therapeutics of HA
Hyaluronidases are a class of enzymes that predominantly degrade
HA (Table 2). Recently, Lokeshwar et al. have shown that the
expression of HYAL-1-v1 in bladder cancer cells that express
wild type HYAL-1 induces G2-M arrest and apoptosis (310). It
has been shown that adhesion of monocytes to human coronary
artery smooth muscle cells was also inhibited by bacterial HYAL
(311). Similarly, commercial bovine testicular or bacterial HYAL
act as an anti-adhesive compound on EMT-6 tumor spheroids
(312), and HYAL disaggregated EMT-6 spheroids increased
chemosensitivity to cyclophosphamide (312), and also improved
the therapeutic effectiveness of these agents, i.e., by increasing
the accessibility of solid tumors to the chemotherapeutic drugs.
Unlike EMT-6 cells, HYALs have limitations as an anti-adhesive
agent for other human tumors (313) and can have side effects that
impact normal tissue functions.
Development of a recombinant soluble form of PH20 (60) has
paved the way for drug delivery in otherwise non-penetrable
pancreatic ductal adenocarcinomas where HA forms a formidable
barrier in the tumor stroma. Intravenous administration of
PEGPH20 restored normal interstitial fluid pressure in the tumor
by increasing vessel diameter. A prospective, randomized, placebo
control trial in KPC mice with combined enzymatic and gemc-
itabine treatment has shown 83% increase inmedian survival rate.
80%placebo controlmice died vs. 29%ofGem+PEGPH20 treated
mice, and significant reduction of metastatic tumor burden was
observed with combined therapy (61).
HA backbone-based conjugated drugs in cancer
Hyaluronan conjugated drugs are more soluble in water than the
drugs alone (Table 2). For instance, the antimitotic chemother-
apeutic agent paclitaxel (PTX) has low water solubility. Upon
conjugation to HA, water solubility of the prodrug HA-PTX, and
of HYTAD1-p20 (a HA-PTX conjugate renamed as ONCOFID-
P by the pharmaceutical company Fidia) significantly increased
CD44 dependent cellular uptake in vitro and in vivo in cancer cells,
including bladder carcinoma cells (314, 315). Luo and Prestwich
coupled PTX-N-hydroxysuccinimide ester (PTX-NHS) with HA
ofmolecularweight ~11 kDa (316). PTX release from the hydrogel
film was evaluated in vitro using selected anti-bacterial and anti-
inflammatory drugs (317). The pharmaceutical company Fidia
prepared ONCOFID™-S, another HA prodrug conjugate with
SN-38, the active CPT11 (irinotecan) metabolite. The HA used
had a molecular weight of ~200 kDa. In vitro and in vivo phase
I and phase II clinical studies were initiated using ONCOFID-
S in several CD44-overexpressing cancer cells, including colon,
gastric, breast, esophageal, ovarian, and human lung cancer cells.
In all these studies, these drugs reduced tumor cell growth and
metastasis (318–320).
HA-encapsulated drugs
Another strategy for HA-based CD44 targeting utilizes the
concept that the large volume domain of HA (molecular
weight> 750 kDa) can non-covalently entrap small therapeutic
molecules within its domain (Table 2). HA was then used as a
macromolecular carrier for the irinotecan drug along with its
targeting properties (321). Clinical trials of threeHA formulations
[termed hyaluronic acid chemo transport technology (HyACT)]
have been undertaken in Australia. Phase I clinical evaluation of
two formulations based on HA (HyACT) with 5-fluorouracil (5-
FU) (known as HyFIVETM), and on HA (HyACT) with doxoru-
bicin (DOX) (known as HyDOXTM) demonstrated reasonable
cytotoxic efficacy without compromising safety of these formu-
lations (322, 323).
HA-tailed drug carriers
These include the following HA conjugates with cytotoxic activity
(Table 2).
(i) Bisphosphonates (BPs) – where HMW HA is linked via a
HABP (324).
(ii) Carbonates (HA-pCB) – where n-propyl carbonate is linked
to HA via an ester linkage (325, 326).
(iii) Chitosan – where chitosan-HA nanoparticles (HA-CTNPs)
containing 5-FU/oxaliplatinwere prepared by the ionotropic
gelation method. 5-FU/oxaliplatin loaded HA-CTNP for-
mulation significantly enhanced cytotoxicity compared with
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either chitosan nanoparticles (CNTPs) alone or free 5-FU,
or oxaliplatin in HT29 CRC cell lines, which overexpress
CD44 (327, 328).
(iv) Gagomers (GAG-mers) – where GAG-mers (GAG clus-
ter of particles) are composed of lipid molecules that self
assemble into particulate clusters in hydrophilic solutions,
which are then covalently coated with HMW (1.2–5MDa)
HA. When tested in primary head and neck cancers and
normal cells taken from the same patient (329), GAG-mers
selectively bound only to the tumor cells to induce cytotoxic
activity.
(v) Liposomes/lipoplexes (HA-LIP) (330–334) – where HMW
HAwas decorated on nano-sized encapsulatedmitomycin C
(MMC). The cytotoxic activity of the drug loaded into HA-
LIP was found to be ~100-fold that of free drug in in vitro
and in vivo tumor cells overexpressing theHA-receptors, but
not in cells with low receptor expression levels. The HA-LIP
conjugate can be used to deliver plasmid DNA and small
interfering RNA (siRNA) to CD44 positive cancer cells (332,
335). The presence of HMWHA in the lipoplexes enhanced
nucleic acid protection from degradation by DNase I or
RNAse VI. In case of LMW HA, the HA was linked to
PE to form a conjugate in which only one PE molecule
is linked to a HA molecule (333, 334). This procedure
enables a controlled amount of HA to be introduced into
the liposomes. oHAs were attached to PE and incorpo-
rated into the liposomes, which increased their recogni-
tion, cytotoxicity, and transfection efficiency by tumor cells
expressing high levels of CD44 in a temperature-dependent
manner.
(vi) Micelles – where the hydrophilic backbone of HA was
conjugated via its carboxyl groups to amino functions of
poly--histidine (PHis) or polyethylene glycol (PEG). These
HA constructs form nanocomplexes by self-organizing into
micelles, and they can carry anticancer drugs, including
PTX. In addition, PTX when entrapped into the hydropho-
bic cores of the folic acid (FA)-conjugated HA-C18 micelles
exhibited higher cytotoxic activity compared to Taxol in
MCF-7 cells that overexpress both the folate receptor and
CD44. The micelles of HA-PTX (336), HA-DOX (337), and
HA-salinomycin (338) exhibited more pronounced cyto-
toxic effects on HA-receptor overexpressing cancer cells
than on receptor deficient cells.
(vii) Nanocarrier – where HA was conjugated to a nanocar-
rier. These nanoparticles were able to deliver anticancer
drugs, including epirubicin (339), DOX (333), PTX (314),
and MMC (339), as well as siRNA, to CD44 overexpress-
ing cells (340). In addition to the well-developed strategies
described above, several multifunctional nanocompounds
have recently been developed that combine therapeu-
tic and diagnostic properties. These nanoparticles include
quantum dots (341), carbon nanotubes (342) and nan-
odots (343), graphene (344), gold nanoparticles (345),
iron oxide nanoparticles (346), and silica nanoparticles
(347), and they have been found to acquire novel char-
acteristics after their conjugation with HA (341–348)
(Table 2).
Targeting CD44 in Cancer
HMW HA can interact with a number of CD44 receptors and be
endocytosed. It is rapidly cleared from circulation by the liver hep-
atocytes (349), and any excess of the targeting compound can lead
to adverse effects (350). This rapid clearance was circumvented by
choosing oHAs long enough to bind to CD44 but too short to bind
to the HARE receptor, which may permit targeting to cells that
overexpress CD44. The minimum HA length required to interact
with individual CD44 molecules is 6–10 monosaccharides (220)
with moderate affinity.
Interrupting HA-CD44 Interaction
As mentioned in the previous sections, the main property
attributed to CD44 is its ability to bind HA, and this binding
contributes to apoptosis resistance of cancer-initiating cells (6,
37, 351–353) (Table 3; Figure 6). There are also examples in
which CD44 cross-linking initiates apoptosis. However, apop-
tosis induction by HA-CD44 cross-linking is largely restricted
to non-transformed cells with immature leukocytes being most
easily affected. Thus, together with the oncogenic transformation
and the pronounced association of CD44 with oncogenes, HA-
CD44 cross-linking initiates signals that promote cell survival
in tumor cells. The cross-talk of CD44 with multidrug resis-
tance genes accounts for an alternative CD44-mediated apop-
tosis resistance mechanism This approach involves substituting
multivalent interaction of HMW HA with CD44 with monova-
lent interaction of small oHAs [6–18 saccharide units (oHAs)]
(217, 354). The oHAs inhibit HA-CD44 downstream cell sur-
vival and proliferation pathways, and they stimulate apoptosis
and expression of phosphatase and tensin homolog (PTEN) (86,
355). The oHAs also sensitize cultured cancer cells to some
chemotherapeutic drugs by inhibiting expression of MDR1 and
other ABC transporters (96, 228, 241). While oHAs inhibit the
growth of several tumors implanted as xenografts (86), they did
not give consistent significant growth inhibition in adenoma
growth in Apc Min/+ mice (Misra et al., unpublished results).
There are several studies contradicting the cellular response of
HMW and LMWHA. For example, in schwannomas cells, HMW
HA inhibited tumor growth (356). In contrast, LMW HA can
induce angiogenesis (80) and inflammatory responses in various
cell types (76, 112, 357). These inconsistencies could be resolved
if the HA preparations and size determinations could be done
properly and if the receptors, or the signaling pathways were
identified properly. Only a few studies define the receptors (93,
232). Thus, we developed siRNA and, even more advantageous,
short hairpin RNA (shRNA), to target CD44v6 in colon can-
cer, and showed that they can successfully interrupt HA-CD44v6
interaction and signaling (~90-95%). We then developed a novel
shRNA delivery approach to target HA-CD44v6 specifically in
tumor cells (6, 94, 95, 248), which is discussed in the following
sections.
Overexpression of sol-CD44 displaces exogenous HA from its
binding to CD44 and thereby retards tumor cell growth both
in vitro and in vivo, and sensitizes tumor cells to chemothera-
peutic drugs (228, 229, 353, 358, 359). However, soluble forms
of CD44 can differ in their capacity to bind HA, indicating
that sol-CD44 can act as a competitive inhibitor of exogenous
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TABLE 3 | CD44 function in cancer.
Disease model Function of CD44 in cancer Approaches to interfere the HA-CD44 interaction Reference
Colon, breast and prostate
cancer cells
Apoptotic resistance HA oligosaccharides [6–18 saccharide units (oHAs)] (86, 96, 219, 230,
243, 356, 357)
Schwannomas cells Inhibition of cell survival HMW HA (358)
Xenografts of mammary
and colon tumor cells
Cell survival Soluble CD44 (166, 230, 231,
355, 360, 361)
HNSCC In vitro and in vivo malignant properties Anti-CD44-Mo-Ab conjugated with mertansine, or
radionucleotide, activated anti-CD44 antibody (H90)
(152, 369–373)
AML cells Tumor cell survival activities CD44v6 peptides containing the v6 exon region (373)





In vitro cell migration, invasion Pep-1 (specific 12-mer HA-binding peptide (379)
Melanoma tumor cells Melanoma tumor cells growing under both anchorage-
dependent and -independent conditions melanoma
tumor growth in nude mice xenograft models
BHP (42 amino acid peptide containing three BX7B
HA-binding motifs) peptide
(362)
Disease model Function of CD44 in cancer Systemic targeting by viral and non-viral vectors Reference
Ornithine transcarbamylase
deficient sparse fur mice
Tumor cell growth in vitro and in vivo Viral vectors (389)
K562 cells Tumor cell growth in vitro and in vivo Non-viral vectors (390, 391)
Intestinal tumors in Apc
Min/+ mice
Tumor cell growth in vitro and in vivo Tissue-specific delivery of non-viral CD44v6
shRNA-nanaoparticle
(94)
A B C D E F G H I
FIGURE 6 | Drug targeting approaches to exploit HA-CD44 interaction
(C) in cancer treatment. (A) HMWHA-CD44v interaction induces inflammation
and tumor growth; most common blocking reagents against CD44 isoforms:
(B) LMW HA inhibits the binding of HMWHA; (C) sol-CD44 competes with
HMWHA to bind with CD44v; (D). CD44-blocking monoclonal antibody
(CD44-mAb); (E) antibodies against CD44v6; (F) peptides blocking binding of
HA with CD44v6; (G) enzymatic hydrolysis by hyaluronidase cleaves the
HMWHA to small fragments and blocks the HA-CD44v6 interaction;
(H) targeting HA receptor with HA-drug conjugate; (I) targeting “HA receptor”
with “HA nanoparticles.”
HA-protein interactions. In these studies, sol-CD44 blocks HA-
activated CD44 clustering and inhibits CD44-mediated recruit-
ment of activated MMP-9 and invasion potential of cancer cells
(165). Similar to HA-binding sol-CD44, a peptide (42 amino
acids in length) enriched with three HA-binding motifs (BX7B)
possesses an antitumor activity in melanoma cancer (360).
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Targeting with Anti-CD44 Antibodies
Anti-CD44 antibodies against highly expressed CD44v vari-
ants can effectively target drugs to cells expressing a selec-
tive CD44v, which can then inhibit and disrupt CD44 matrix
interactions, alter CD44 signaling, and cause apoptosis (361)
(Table 3; Figure 6). Antibodies against highly expressed vari-
ants can also be designed to selectively deliver a cytotoxic drug
to cancer cells in two different ways. They can bind and neu-
tralize the receptor by competitive inhibition of its ligand and
hence stop the receptor-signaling cascade. They can also be
attached to radioisotopes, toxins, or chemotherapeutic agents
and target them to the required vicinity. The first concept
has been effectively utilized for other receptors like anti-EGFR
antibodies cetuximab, panitumumab, etc. Anti-CD44v6 conju-
gated with a cytotoxic drug mertansine has been extensively
studied in early phase clinical trials for its value in transla-
tional medicine (362–366). Head and neck squamous cell cancer
(HNSCC) patients were treated with three doses of mertansine
conjugated bivatuzumab (humanized anti-CD44v6 monoclonal
antibody [HAMA] labeled with technetium-99m) was first tested
(151, 367, 368). However, the phase I clinical trials were rather
disappointing in terms of accumulation and toxicity. Further-
more, dose limiting skin toxicity was observed, most probably
due to CD44v6 expression in non-tumor skin areas, indicat-
ing limitations in the use of this antibody therapy. However,
given the promising results of a phase I clinical study with the
radionuclide-antibody conjugates (362–366), new similar conju-
gates of bivatuzumab with radioisotopes were found to be safe
and effective in phase I trials (369, 370), and a conjugate of
immunotoxin with bivatuzumab (369) was also found to be safe
in the next clinical trial on 30 HNSCC patients. In this con-
text, a previous study showed that activated anti-CD44 antibody
(H90), when used in human acute myeloid leukemia (AML)
cells, reduced the leukemic repopulation by altering the fate of
AML leukocyte stem cells (AML LSC), and by abrogating AML
LSC homing, leading to their death (371). This study suggests
that activated anti-CD44 antibodies without conjugation with
toxin are much safer and efficient for antitumor activity. Thus,
CD44, particularly CD44 variant forms, remains a crucial target
for tumor therapy (Figures 4 and 5). To address this issue, we
have developed a novel tissue-specific (CD44v6) shRNA delivery
strategy by a Cre-lox system. This technology is discussed in a
following section.
Peptide-Based Strategies
It is becoming increasingly evident that future prospects for the
treatment of inflammation/cancer should include the targeting of
specific signaling pathways in tumor cells. (Table 3; Figure 6)
CD44v6 is a co-receptor for VEGF/VEGFR-2 and HGF/c-Met,
and mutational analysis of CD44v6 revealed that three amino
acids in the v6 region are required for its co-receptor function
for Met and VEGFR-2. These studies helped to identify CD44v6
peptides with the minimal length of five amino acids that contain
the critical v6 exon region that can inhibit both VEGFR-2 and c-
Met activation. This inhibits the co-receptor function of CD44v6
and the vascularization and tumor cell growth, migration and
invasion (103, 372).
Serine phosphorylation of the human CD44 cytoplasmic tail
at Ser323 and Ser325 enhances cell migration potency. Thus,
a penetratin-conjugated peptide containing phosphoserine at
residue 325 reduced in vitro migration of melanoma cells (373).
Insertion of phosphorylated Ser325 (pSer325) or pSer323 and
pSer325 in the peptides disrupted the activation of CD44/MMP-9
signaling complex in prostate cancer cells (374). Another peptide
comprising eight amino acids that bind specifically to CD44 (375)
and derived from human urokinase plasminogen activator (A6)
inhibits migration, invasion, and metastasis of cancer cells by
interfering with an uPA-independent signaling pathway (376).
The Pep-1 (specific 12-mer HA-binding peptide) peptide can
reduce lung metastasis and prolong survival of mice injected
with cell line-derived melanoma cells (377). Besides this Pep-
1, BH-P, a 42 amino acid peptide containing three BX7B HA-
binding motifs present in CD44 can exert antitumor effects by
inhibiting the proliferation of melanoma tumor cells growing
under both anchorage-dependent and -independent conditions
and by inhibitingmelanoma tumor growth in nudemice xenograft
models (360).
Tissue-Specific Deletion of CD44variant Signaling
CD44 splicing can regulate interaction with HA (378, 379)
(Table 3; Figure 6). HA is not only the essential component of
the tumor matrix assembly (380), but also has a crucial role in
cancer stem cell (CSC) niches, which are particularly rich in HA
(381). Interference in matrix components alters signaling events
of tumor-initiating cells such that tumor cells that express HA
can induce expression of HA in other cells that make up the
CSC niche (382, 383). In addition, CD44v6 isoforms are engaged
in matrix assembly (384) and have been identified as markers
of CSCs in colon cancer, and they account for the metastatic
susceptibility of the tumors (385). In the intestinal mucosa, CD44
is a major direct target of β-catenin mediated transcription (177),
and we have shown that CD44v6 also regulates β-catenin in colon
cancer cells (93). Furthermore, CD44v4-v10, but not CD44s, is
a crucial component of the intestinal stem cells in the crypts of
ApcMin/+ mice, and controls tumor initiation and relapse by
controlling the balance between cell survival and apoptosis (178).
These studies indicate that CD44v6 targeting in colon cancer
is a promising therapeutic approach. The inhibition of CD44
mRNA expression by inducing the expression of siRNA/shRNA
in tumor cells is an alternative approach to the use of CD44-
blocking antibodies to interfere with the function of CD44 pro-
teins. This section discusses the fundamental aspects of a ther-
apeutic approach targeting CD44v6 by means of colon cancer
cell-specific delivery of shRNA. This approach addresses: (a) what
to deliver (engineered therapeutic CD44v6 shRNA), (b) how
to deliver (delivery strategies using non-viral transferrin (Tf)-
coated PEG-polyetheleneimine (PEI) (Tf-PEG-PEI) nanoparticles
for in situ cell-specific therapy), and (c) where to deliver (tumor
cell targets, in particular, colon tumor cells for in situ cell-specific
therapy). The technique of using shRNA in an expression vector is
an alternative strategy to stably suppress selected gene expression,
which suggests that the use of shRNA expression vectors holds
potential promise for therapeutic approaches for silencing disease
causing genes (386). There are two ways to deliver shRNA in
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cancer cells, either using a viral vector or a non-viral vector. Viral
vectors have been used to achieve proof of principle in animal
models and, in selected cases, in human clinical trials (387).
Systemic targeting by viral vectors toward the desired tissue is
difficult because the host immune responses activate viral clear-
ance. Systemic administration of a large amount of adenovirus
(e.g., into the liver) can also be a serious health hazard and even
caused the death of one patient (387). Nevertheless, there has
been considerable interest in developing non-viral vectors for gene
therapy.
Figures 6–8 illustrate themodel for the uptake of non-viral vec-
tors through Tf-PEG-PEI-nanoparticles carrying multiple func-
tional domains. Non-viral vectors mediate unspecific interactions
with non-target cells and blood components, which results in the
rapid clearance from circulation. PEI has positive charges and
binds to negatively charged plasmid DNA to form condensed
particles. The PEG shields the condensed PEI-Plasmid particles
from unwanted interactions and prevents clearance from circula-
tion thus giving longer half-life (388). To increase the transfection
efficiency of the shielded particles (plasmid DNA/PEG-PEI), dif-
ferent targeting ligands, such as peptides, growth factors and
proteins, or antibodies, have been incorporated into the vec-
tors (389). One such targeting ligand is Tf, an iron-transporting
protein that is recognized by Tf receptors (Tf-Rs). Association
of Tf to polyplexes enhances transfection efficiency (389). This
concept was tested by preparing non-viral vector Tf-PEG-PEI-
nanoparticles with plasmids packed inside an outer PEG-PEI layer
coated with Tf that binds with Tf-R with high affinity in the
tumor cells (94, 389, 390) (depicted in the model in Figure 7).
We found that the Tf-R is present at much higher levels on the
tumor cells than on phenotypically normal epithelial cells (94).
Tf-PEG-PEI-nanoparticles significantly enhance transfection effi-
ciency of CD44v6 shRNA generator plasmids by promoting the
internalization of the nanoparticles in proliferating and non-
proliferating colon cells through receptor-mediated endocytosis
(94, 389). Therefore, the uptake of Tf-PEG-PEI-nanoparticles car-
rying multiple functional domains (surface shielding particles
Tf-PEG-PEI, CD44v6 shRNA generator plasmids, tissue-specific
promoter driven Cre recombinase plasmids, and conditionally
silenced plasmids) can overcome the intracellular barriers for
successful delivery of the CD44v6 shRNA (94).
This CD44v6 shRNA plasmid delivery approach was tested
for transfection of pSV-β-gal/Tf-PEG-PEI-nanoparticles in cel-
lular models (6, 94, 248) (Figure 7). Following this experi-
ment, we successfully demonstrated that the CD44v6 shRNA is
localized into the colon tumor cells by an end point assay of
CD44v6 expression and by perturbation of HA-CD44v6 interac-
tion as reflected in the reduction in the number of tumors (94).
FIGURE 7 | Schematic illustration of cellular uptake of plasmid
DNA/Tf-PEG-PEI (nanoparticles) polyplexes, their shielding from
non-specific interaction, and the mechanism of action of shRNA.
Internalization of PEG-shielded and [transferrin receptor (Tf-R)]-targeted
polyplexes into target cells occurs by receptor-mediated endocytosis after
association of polyplex ligand Tf to Tf-R present on the target cell plasma
membrane. Internalized particles are trafficked to endosomes followed by
endosomal release of the particles and/or the nucleic acid into cytoplasm.
Released siRNA will form a RNA-induced silencing complex and will be guided
for cleavage of complementary target mRNA in the cytoplasm. SiRNA
(antisense) guide strand will direct the targeted RNAs to be cleaved by RNA
endonuclease. Finally, plasmid/Tf-PEG-PEI-nanoparticles delivery in the target
cell shows reporter gene expression and activity. The normal tissue cells are not
affected because they do not make the targeted CD44 variant. Tf-PEG-PEI
nanoparticle coated plasmids (pSico-CD44v6 shRNA/pFabpl-Cre) circulating in
blood accumulate at tumor regions enhanced by the EPR effect. Endocytosis
mediated by ligand-receptor interactions occurs because the nanoparticles are
coated with the Tf-ligand for the Tf-R receptor on the tumor cell surface.
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FIGURE 8 | Exploitation of HA-CD44 interaction for anticancer
therapy. Left panel shows a schematic diagram for cancer cell
internalization of HA conjugated to a drug inhibitor of DNA synthesis. CD44
on the membrane traps the HA-drug conjugate and efficiently internalizes it
by endocytosis and forms an endosomal vesicle. This is then transported to
the lysosome and fused, and the internalized HA is degraded by
hyaluronidase 1 (Hyal-1) into small HA oligosaccharides and then to
monosaccharides by lysosomal glycosidases, which ultimately releases the
conjugated drug. The drug then goes to the nucleus and inhibits the DNA
synthesis. Right panel shows targeting the CD44v6mRNA in cancer cells by
CD44v6 shRNA. Plasmids that produce CD44v6 shRNA are coated with
transferrin present on the outer surface of the nanoparticles. The transferrin
molecules then target the transferrin receptors present in high amounts on
the cancer cells. Upon internalization, an endosome forms and the plasmids
are released to the nucleus where CD44v6 shRNA is produced by DNA pol
III. The shRNA is then exported out of the nucleus by exportin, and the dicer
enzyme converts shRNA into CD44v6 siRNA. One of the strands of siRNA
will bind to CD44v6 mRNA and form a RISC (RNA-induced silencing
complex) that is ultimately degraded. Adapted from our article in the
International Journal of Cell Biology.
The tissue-specific shRNA delivery was made possible by the
use of Cre-recombinase produced in response to a colon tissue-
specific promoter, which deletes the interruption between the U6
promoter and the CD44v6 shRNA oligonucleotide. The newly
developed cell-specific shRNA delivery approach by Misra et al.
(94) confirmed that targeting the signaling pathways induced by
HA-CD44v6 interaction inhibited distant colon tumor growth in
Apc Min/+ mice. Our recent unpublished in vivo studies with
the C57Bl/6 mice have now shown that systemic delivery of a
mixture of two plasmids, prostate-specific Probasin-Cre/Tf-PEG-
PEI-nanoparticles and floxed pSico-CD44v9shRNA/Tf-PEG-PEI-
nanoparticles, can target both localized and metastatic prostate
cancer cells. This novel approach opens up new ways to combat
cancer and to understand tumorigenesis in vivo for the following
reasons (Figure 7).
(i) Cell-specific shRNA to CD44variant (CD44vshRNA) is
released by applying a tissue-specific promoter driven Cre-
lox mechanism.
(ii) This shRNA silences the expression of the selected CD44
variant in the target tissue cancer cells.
(iii) This shRNA does not affect the normal target tissue cells,
which rely on the standard CD44s and do not express the
targeted CD44variant, and therefore are not affected by the
plasmids.
(iv) The target CD44vshRNAwill not be expressed in other types
of cells because the tissue-specific promoter only unlocks the
Cre-recombinase in the targeted tissue cells, which reduces
potential side effects (94).
(v) The Tf-PEG-PEI-nanoparticles that carry plasmids are
biodegradable and cleared from the system.
(vi) This method inhibits the pathophysiological role of HA-
CD44v interactions in cancer.
(vii) It can establish diagnostic markers for the targeted cancer,
including CD44variants, soluble CD44, and HA.
(viii) It can identify HA-CD44v interactions as innovative novel
therapeutic targets against cancer progression.
Thus, the conditional suppression of gene expression by the use
of a CD44vshRNA expressing plasmid holds potential promise for
therapeutic approaches for silencing HA-CD44variant signaling
and downstream signaling pathways that promote disease causing
genes (386).
Targeting RHAMM in Cancer
Under homeostatic condition, RHAMM expression is very low.
Its expression is increased during pathogenesis (inflammation and
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TABLE 4 | RHAMM function in cancer.
Disease model Function of RHAMM in cancer Approach using HA-binding peptide Reference
Esophageal squamous cell carcinoma Invasiveness Pep-1 (393)
Multiple myeloma and myelodysplasia syndrome Anti-apoptosis RHAMM-R3 peptides (394, 395)
Malignant peripheral nerve sheath tumors or multiple myeloma Apoptotic resistance RHAMM silencing (396–398)
Neuroblastoma tumors Apoptotic resistance RHAMM-based immunotherapies
targeting AURKA and BARD1
(399, 400)
Acute myeloid leukemia Antitumor activity RHAMM R3 (395, 401)
cancer) (132). Such a restricted expression of RHAMM makes it
a suitable target for cancer and wound repair therapy with low
toxicity (132).
RHAMM-Based Immunotherapies
Peptides that mimic either RHAMM itself or the HA sizes that
bind to RHAMM have been shown to affect neoplastic processes
as well as inflammation and wound repair (Table 4). HA targeting
by Pep-1 blocked esophageal squamous cell carcinoma invasive-
ness by inhibiting HA-RHAMM induced effects (391). There is
evidence that RHAMM-R3peptides that are currently being tested
in phase II clinical trials for multiple myeloma and myelodys-
plastic syndrome show efficacy and low toxicity in patients (392,
393). RHAMM silencing abrogated the self-renewing property
of glioblastoma stem cells, and loss of RHAMM in malignant
peripheral nerve sheath tumors or multiple myeloma sensitizes
tumor cells to inhibitors (394–396). Neuroblastoma tumors are
also sensitive to RHAMM-based immunotherapies due to the
established roles of AURKA (397) and BARD1 [breast cancer gene
1 (BRCA1)-associated ring domain protein-1] (398), two com-
ponents of the AURKA-BRCA1/BARD1-RHAMM-TPX2 centro-
some module, within this refractory disease (267).
Cell-Based Therapies
In addition, cell-based strategies using peptide vaccination
with a RHAMM-derived, highly immunogenic peptide, termed
RHAMM R3, has proven safe and effective at generating CD8+
RHAMM-specific T cell cytotoxic cellular responses and antitu-
mor activity in patients with AML, myelodysplastic syndrome,
multiple myeloma, and, more recently, chronic lymphocytic
leukemia in phase I/II trials (393, 399) (Table 4). These stud-
ies provide evidence that blocking RHAMM is a promising
immunotherapy approach in patients with hematological malig-
nancies. In another study, antitumor activity has also been
reported for vaccinationwith dendritic cells expressing exogenous
RHAMMmRNA in a mouse model of glioma (400).
A handful of RHAMM-based therapeutical studies in cancer
suggest that more intense studies should be undertaken to deter-
mine how RHAMM signaling contributes to cancer progression.
Although HA-receptor-mediated signaling is believed to be a
promising anticancer/anti-inflammatory drug target, given the
dual functions of HA, CD44 and RHAMM in the inflamma-
tory/tumorigenic responses, caution must be taken in consider-
ing therapeutic targeting of these molecules, which should be
designed for specific organs and specific diseases with consider-
ation of the use of proper sizes of endotoxin free HA, whichmight
provide a way to prevent side effects.
Conclusion
In the past few years, basic and clinical research on CD44 have
identified the genomic DNA structure and alternative splicing
pattern of CD44, which has led to a conclusion that CD44v is
not one but a family of proteins, and that discrete isoforms are
expressed and regulated at various stages of oncogenic transfor-
mation. Most, but not all, cancers overexpress discrete species
of CD44v, which can be correlated with tumor aggressiveness.
A challenging area of research would be to define what cellular
functions are associated with the various CD44 isoforms that are
overexpressed in various cancers before a CD44-based therapy
can be undertaken. Considering the biological functions of HA
particularly the connection of such function with molecular size
of HA, the HA-binding proteins, its spatial and temporal distri-
bution in tissues, and the cellular background and tissue stages,
care must be taken to ensure the long-term safety of HA-based
bioconjugates. Thus, this review defines the origins of evidence
for a linkage between HA, CD44v, and RHAMM expression with
inflammatory diseases, includingmalignancy, and emphasizes the
most advanced and developed therapeutic strategies, those that
have either been used for clinical trial or are nearly ready to get
there. In addition, approaches used in various preclinical models
are also briefly reviewed. Studies reviewed here identified strong
prospects for anti-CD44 therapies. TheHA-CD44 interaction sys-
tem is illustrated inFigure 8wherewe specify cancer therapeutical
aspects (discussed in this review) that specifically perturb HA-
CD44 signaling pathways. Interference with the function of HA-
CD44 can inhibit the inflammation/malignant processes at mul-
tiple stages. This can be accomplished by perturbing HA-CD44
signaling pathways, by disruption of theHAmatrixwithHYALs to
facilitate passive carrier uptake and providing a sustained source
of drug at the tumor site, by targeting CD44with a CD44-blocking
antibody, or by tissue-specific targeting of specific variants of
CD44v that are overexpressed in tumors (Figure 8).
Although overexpression of CD44 correlates with bad prog-
nosis in patients with most human cancers (151, 178–184), it
was also found that CD44 is extremely sensitive to changes in
the microenvironment. For example, CD44 in breast cancer cells,
neuroblastomas and prostate cancer may act as a metastatic sup-
pressor gene (170, 185, 186), suggesting that the growth promoting
pathways in these tumors are independent of CD44. These differ-
ential regulations should be considered carefully while designing
CD44 as a target for therapeutic strategy.
For last two decades, several studies were dedicated to the
use of CD44v, in particular CD44v6, as a therapeutic target. As
discussed in Section “Targeting with Anti-CD44 Antibodies,” the
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anti-CD44v6 antibody conjugated with mertansine showed dose
limiting skin toxicity due to CD44v6 expression in non-tumor
skin tissue. However, the scientific progress in the last few
years provides strong support for using CD44v as a target for
therapeutic strategies. This is due to the fact that: (1) CD44v6
is a marker for colon CSCs (180, 385); (2) CD44v6 can act
as co-receptor for at least three RTKs (c-Met, VEGFR-2, and
EGFR) (103, 236, 401), and many of the oncogenic functions
of CD44v6 can be attributed to downstream signaling induced
by these RTKs; and (3) CD44v6 is highly expressed in many
cancers. Nevertheless, there is an urgent need to define which
CD44v variants are present on the CSCs for the particular type
of cancer, and then target them in signaling complex tissue
specifically by non-viral vectors. Collectively, these studies sug-
gest that future development of drug targeting approaches can
use tissue-specific expression of CD44v-specific antagonists as
well as inhibitors (agents that are currently used in the clinic)
targeting CD44 isoforms and their co-receptors/ligands that
alter intracellular signaling in the inflammatory/tumor tissue
microenvironment, as an effective and novel approach to reg-
ulate these diseases. Finally, since CD44 and RHAMM bind to
HA, targeting against RHAMM may be an additional treatment
option.
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